Plus Therapeutics (PSTV) REYOBIQ Receives Orphan Drug Status

The FDA has granted orphan drug status to Plus Therapeutics' (PSTV) REYOBIQ. This designation is intended to facilitate the development of treatments for rare diseases and can provide various benefits, including tax credits and market exclusivity. Orphan drug status is crucial for companies seeking to invest in therapies for conditions affecting fewer than 200,000 patients in the U.S. This development may influence investor sentiment and market valuation for Plus Therapeutics (PSTV).